Table 1. Comparison of clinicopathological features of two groups.
| Characteristics | All patients (n = 1096) | P | Patient propensity matching (n = 692) | P | ||
|---|---|---|---|---|---|---|
| LATG (n = 510) | OTG (n = 586) | LATG (n = 346) | OTG (n = 346) | |||
| Age | 62.3 ± 11.2 | 60.4 ± 10.2 | 0.003 | 61.1 ± 10.0 | 61.3 ± 10.1 | 0.952 |
| Gender | 0.808 | 1.000 | ||||
| Male | 406 (79.6) | 463 (79.0) | 274 (79.2) | 274 (79.2) | ||
| Female | 104 (20.4) | 123 (21.0) | 72 (20.8) | 72 (20.8) | ||
| BMI (kg/m2) | 21.9±2.8 | 22.0 ± 2.1 | 0.395 | 22.0 ± 2.9 | 22.0 ± 2.3 | 0.645 |
| Tumor location | 0.001 | 0.885 | ||||
| Upper | 258 (50.6) | 341 (58.2) | 191 (55.2) | 188 (54.3) | ||
| Middle | 219 (42.9) | 188 (32.1) | 136 (39.3) | 136 (39.3) | ||
| Total | 33 (6.5) | 57 (9.7) | 19 (5.5) | 22 (6.4) | ||
| Tumor size (cm) | 5.6 ± 2.7 | 5.9 ± 2.9 | 0.083 | 6.1 ± 3.11 | 6.0 ± 2.6 | 0.774 |
| Histologic type | < 0.001 | 0.920 | ||||
| Differentiated | 83 (16.3) | 180 (30.7) | 60 (17.3) | 59 (17.1) | ||
| Undifferentiated | 427 (87.7) | 406 (69.3) | 286 (82.7) | 287 (82.9) | ||
| pT stage | < 0.001 | 1.000 | ||||
| T1 | 70 (13.7) | 54 (9.2) | 34 (20.2) | 34 (21.1) | ||
| T2 | 49 (9.6) | 49 (8.4) | 25 (20.2) | 25 (21.1) | ||
| T3 | 148 (29.0) | 78 (13.3) | 63 (16.9) | 63 (13.6) | ||
| T4a | 243 (47.6) | 405 (69.1) | 224 (62.9) | 224 (65.3) | ||
| pN stage | 0.036 | 0.163 | ||||
| N0 | 155 (30.4) | 162 (27.6) | 67 (19.4) | 92 (26.6) | ||
| N1 | 78 (15.3) | 65 (11.1) | 61 (17.6) | 48 (13.9) | ||
| N2 | 91 (17.8) | 95 (16.2) | 61 (17.6) | 56 (16.2) | ||
| N3a | 109 (21.4) | 164 (28.0) | 88 (25.4) | 91 (26.3) | ||
| N3b | 77 (15.1) | 100 (17.1) | 69 (19.9) | 59 (17.1) | ||
| pTNM stage | < 0.001 | 0.735 | ||||
| IA | 60 (11.8) | 49 (8.4) | 29 (8.4) | 30 (8.7) | ||
| IB | 34 (6.7) | 40 (6.8) | 17 (4.9) | 21 (6.1) | ||
| IIA | 49 (9.6) | 28 (4.8) | 13 (3.8) | 22 (6.4) | ||
| IIB | 68 (13.3) | 74 (12.6) | 40 (11.6) | 40 (11.6) | ||
| IIIA | 70 (13.7) | 56 (9.6) | 49 (14.2) | 41 (11.8) | ||
| IIIB | 97 (19.0) | 109 (18.6) | 69 (19.9) | 68 (19.7) | ||
| IIIC | 132 (25.9) | 230 (39.2) | 129 (37.3) | 124 (35.8) | ||
| Postoperative chemotherapy | 0.170 | 0.287 | ||||
| Yes | 413 (81.0) | 493 (84.1) | 310 (89.6) | 301 (87.0) | ||
| No | 97 (19.0) | 93 (15.9) | 36 (10.4) | 45 (13.0) | ||
| No. of comorbidities | 0.794 | 0.317 | ||||
| 0 | 362 (71.0) | 418 (71.3) | 241 (69.7) | 249 (72.0) | ||
| 1 | 109 (21.3) | 117 (20.0) | 82 (23.7) | 68 (19.7) | ||
| 2 | 35 (6.9) | 43 (7.3) | 21 (6.0) | 23 (6.6) | ||
| ≥ 3 | 4 (0.8) | 8 (1.4) | 2 (0.6) | 6 (1.7) | ||
BMI: body mass index; No. of comorbidities: number of comorbidities